- Home
- TEI vs OTLK Comparison
TEI vs OTLK Comparison
Compare TEI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | OTLK |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TEI | OTLK |
|---|---|---|
| Price | $6.71 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 128.5K | ★ 15.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $0.16 |
| 52 Week High | $7.00 | $3.39 |
Technical Indicators
Market Signals| Indicator | TEI | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 65.88 | 59.67 |
| Support Level | $6.24 | $0.26 |
| Resistance Level | $6.94 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 92.31 | 42.11 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.